The development and validation of a decision-analytic model representing the full disease course of acute myeloid leukemia.

Abstract

BACKGROUND The treatment of acute myeloid leukemia (AML) is moving towards personalized medicine. However, due to the low incidence of AML, it is not always feasible to evaluate the cost-effectiveness of personalized medicine using clinical trials. Decision analytic models provide an alternative data source. OBJECTIVE The aim of this study was to develop… (More)
DOI: 10.1007/s40273-013-0058-1

Topics

Cite this paper

@article{Leunis2013TheDA, title={The development and validation of a decision-analytic model representing the full disease course of acute myeloid leukemia.}, author={Annemieke Leunis and W. Ken Redekop and Kees C. A. G. M. van Montfort and Bob L{\"o}wenberg and Carin A. Uyl-de Groot}, journal={PharmacoEconomics}, year={2013}, volume={31 7}, pages={605-21} }